379 related articles for article (PubMed ID: 31345258)
1. Barriers and facilitators to office-based opioid agonist therapy prescribing and effective interventions to increase provider prescribing: protocol for a systematic review.
Nixon LL; Marlinga JC; Hayden KA; Mrklas KJ
Syst Rev; 2019 Jul; 8(1):186. PubMed ID: 31345258
[TBL] [Abstract][Full Text] [Related]
2. Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review.
Leece P; Khorasheh T; Corace K; Strike C; Bayoumi AM; Taha S; Marks E; Pach B; Ahamad K; Grennell E; Holowaty M; Manson H; Straus SE
BMJ Open; 2019 Dec; 9(12):e032285. PubMed ID: 31843837
[TBL] [Abstract][Full Text] [Related]
3. Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities.
Hagedorn H; Kenny M; Gordon AJ; Ackland PE; Noorbaloochi S; Yu W; Harris AHS
Addict Sci Clin Pract; 2018 Dec; 13(1):25. PubMed ID: 30545409
[TBL] [Abstract][Full Text] [Related]
4. Barriers and facilitators for family physicians prescribing opioid agonist therapy in Saskatchewan.
Nguyen T; Bareham J; Halpape K
Can Fam Physician; 2024 Apr; 70(4):e52-e60. PubMed ID: 38626996
[TBL] [Abstract][Full Text] [Related]
5. Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey.
Kouyoumdjian FG; Patel A; To MJ; Kiefer L; Regenstreif L
PLoS One; 2018; 13(2):e0192431. PubMed ID: 29447177
[TBL] [Abstract][Full Text] [Related]
6. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
7. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
[TBL] [Abstract][Full Text] [Related]
8. Optimising treatment in opioid dependency in primary care: results from a national key stakeholder and expert focus group in Ireland.
Van Hout MC; Crowley D; McBride A; Delargy I
BMC Fam Pract; 2018 Jun; 19(1):103. PubMed ID: 29960593
[TBL] [Abstract][Full Text] [Related]
9. Prescriber Education Interventions to Optimize Opioid Prescribing in Acute Care: A Systematic Review.
Hopkins RE; Bui T; Magliano D; Arnold C; Dooley M
Pain Physician; 2019 Nov; 22(6):E551-E562. PubMed ID: 31775401
[TBL] [Abstract][Full Text] [Related]
10. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
[TBL] [Abstract][Full Text] [Related]
11. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
Rhee TG; Rosenheck RA
Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
[TBL] [Abstract][Full Text] [Related]
12. A survey of barriers and facilitators to the adoption of buprenorphine prescribing after implementation of a New Jersey-wide incentivized DATA-2000 waiver training program.
Nyaku AN; Zerbo EA; Chen C; Milano N; Johnston B; Chadwick R; Marcello S; Baston K; Haroz R; Crystal S
BMC Health Serv Res; 2024 Feb; 24(1):179. PubMed ID: 38331802
[TBL] [Abstract][Full Text] [Related]
13. Barriers to primary care physicians prescribing buprenorphine.
Hutchinson E; Catlin M; Andrilla CH; Baldwin LM; Rosenblatt RA
Ann Fam Med; 2014; 12(2):128-33. PubMed ID: 24615308
[TBL] [Abstract][Full Text] [Related]
14. Determinants of selection into buprenorphine/naloxone among people initiating opioid agonist treatment in British Columbia.
Homayra F; Hongdilokkul N; Piske M; Pearce LA; Zhou H; Min JE; Krebs E; Nosyk B
Drug Alcohol Depend; 2020 Feb; 207():107798. PubMed ID: 31927163
[TBL] [Abstract][Full Text] [Related]
15. Buprenorphine prescribing practice trends and attitudes among New York providers.
Kermack A; Flannery M; Tofighi B; McNeely J; Lee JD
J Subst Abuse Treat; 2017 Mar; 74():1-6. PubMed ID: 28132694
[TBL] [Abstract][Full Text] [Related]
16. The Future of Opioid Agonist Therapies in Ukraine: A Qualitative Assessment of Multilevel Barriers and Ways Forward to Promote Retention in Treatment.
Bojko MJ; Mazhnaya A; Marcus R; Makarenko I; Islam Z; Filippovych S; Dvoriak S; Altice FL
J Subst Abuse Treat; 2016 Jul; 66():37-47. PubMed ID: 27211995
[TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. Changes in Opioid Agonist Treatment Practice in Germany during the COVID-19 Pandemic: What Have Physicians Done, and What Would They Like to Keep Doing?
Lehmann K; Kuhn S; Schulte B; Verthein U
Eur Addict Res; 2023; 29(5):323-332. PubMed ID: 37557092
[TBL] [Abstract][Full Text] [Related]
19. Barriers and facilitators to nurse practitioner buprenorphine prescribing for opioid use disorder in primary care settings.
Speight C; Caiola C; Tyndall DE; Scott ES
J Am Assoc Nurse Pract; 2023 Feb; 35(2):112-121. PubMed ID: 36512806
[TBL] [Abstract][Full Text] [Related]
20. Supervised dosing with a long-acting opioid medication in the management of opioid dependence.
Saulle R; Vecchi S; Gowing L
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011983. PubMed ID: 28447766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
